LOGIN  |  REGISTER
Assertio
Recursion

Artivion to Present at the Deutsche Bank 31st Annual Leveraged Finance Conference

September 26, 2023 | Last Trade: US$27.48 0.02 0.07

ATLANTA, Sept. 26, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will present at the upcoming Deutsche Bank 31st Annual Leveraged Finance Conference on Tuesday, October 3, 2023. The Company's presentation is scheduled to begin at 10:40 a.m. MST.

A live webcast of the presentation will be accessible through Artivion's website, www.artivion.com, on the Investors page. An archived copy of the webcast will be available for 90 days on the same website.

About Artivion, Inc.

Headquartered in suburban Atlanta, Georgia, Artivion, Inc. is a medical device company focused on developing simple, elegant solutions that address cardiac and vascular surgeons' most difficult challenges in treating patients with aortic diseases. Artivion's four major groups of products include: aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues. Artivion markets and sells products in more than 100 countries worldwide. For additional information about Artivion, visit our website, www.artivion.com.

Contacts:

  

Artivion

 

Gilmartin Group LLC

D. Ashley Lee

 

Brian Johnston / Lynn Lewis 

Executive Vice President &

 

Phone: 332-895-3222

Chief Financial Officer

 

This email address is being protected from spambots. You need JavaScript enabled to view it.

Phone: 770-419-3355

  
   

Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB